ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by von der Hardt, K.
Right arrow Articles by Dötsch, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von der Hardt, K.
Right arrow Articles by Dötsch, J.
Eur Respir J 2004; 24:615-623
Copyright ©ERS Journals Ltd 2004

Brief adrenomedullin inhalation leads to sustained reduction of pulmonary artery pressure

K. von der Hardt1, M.A. Kandler1, M. Chada1, A. Cubra1, E. Schoof1, K. Amann2, W. Rascher1 and J. Dötsch1

1 Klinik für Kinder und Jugendliche und 2 Pathologisches Institut, der Friedrich-Alexander-Universität, Erlangen-Nürnberg, Germany.

CORRESPONDENCE: M.A. Kandler, Klinik für Kinder und Jugendliche, Loschgestrasse 15, D-91054 Erlangen, Germany. Fax: 49 91318535867. E-mail: michael.kandler@web.de

Keywords: Acute respiratory distress syndrome, adrenomedullin, aerosol, endothelin-1, pulmonary hypertension

Received: February 12, 2003
Accepted May 28, 2004

Supported by a grant from the IZKF (center for interdisciplinary clinical research), University Erlangen-Nürnberg, German Ministry for Education and Research, No. 01 KS 0002, Project C11.

The effect of aerosolised adrenomedullin (ADM), a potent vasodilator peptide, on pulmonary artery pressure was studied for 24 h in a surfactant-depleted piglet model.

Animals received either aerosolised ADM (50 ng·kg–1·min–1, ADM, n=6), or aerosolised normal saline solution (control, n=6). Aerosol therapy was performed for a 2 h treatment period followed by a 22 h observation period. Ventilator settings were adapted to keep arterial oxygen tension and carbon dioxide arterial tension between 13.3–14.6 kPa and 4.9–5.7 kPa, respectively.

Aerosolised ADM reduced mean pulmonary artery pressure (MPAP) compared with the control group (end-point median 24 h after therapy start: {Delta}MPAP –14.0 versus –8.0 mmHg; 23.5 h after therapy start). After therapy start, mean systemic arterial pressure (MAP) was not significantly different between the groups (end-point median: MAP ADM 70 (61/74) versus control 72 (54/81) mmHg). Endothelin-1, a potent pulmonary vasoconstrictor, is regulated by ADM via cAMP. Twenty two hours after inhalation of aerosolised ADM, endothelin-1 mRNA in lung tissue and endothelin-1 protein expression in pulmonary arteries was reduced compared with controls (median semi-quantitative immunhistochemical score: ADM 0.21, control 0.76).

Aerosolised adrenomedullin significantly reduced mean pulmonary artery pressure independently of arterial oxygen tension.




This article has been cited by other articles:


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. I. Said
Mediators and modulators of pulmonary arterial hypertension
Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L547 - L558.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M. Westphal, M. Booke, and A.T. Dinh-Xuan
Adrenomedullin: a smart road from pheochromocytoma to treatment of pulmonary hypertension
Eur. Respir. J., October 1, 2004; 24(4): 518 - 520.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the European Respiratory Society.